Tombak, AnılTanrıkulu, Funda PepedilDurusoy, Salih SertaçGürkan, EmelKaya, EminUmit, Elif G.Yavaşoğlu, İrfanMehtap, ÖzgürDeveci, BurakÖzcan, Mehmet AliTerzi, HaticeOkay, MufideSayınalp, NilgünYılmaz, MehmetOkan, VahapKızıklı, AlperenÖzcan, ÖmerÇetin, GuvenDemircioglu, SinanAydogdu, IsmetSaydam, GurayDavulcu, Eren Arslanİlhan, GulUcar, Mehmet AliÖzet, GulsumAkpinar, SevalTurgut, BurhanBerber, İlhamiKurtoglu, ErdalSonmez, MehmetBatur, Derya SelimYildirim, RahsanÖzkocaman, VildanGunes, Ahmet KursatSahip, BirsenErtop, SehmusAkay, MeltemBasturk, AbdulkadirDogu, Mehmet HilmiAkdeniz, AydanÜnal, AliSeyhanli, AhmetFerhanoglu, Burhan2024-12-042024-12-042019-11-130006-4971https://doi.org/10.1182/blood-2019-126402https://ashpublications.org/blood/article/134/Supplement_1/5476/425188/Efficacy-and-Safety-of-Ibrutinib-Use-in-Patientshttps://hdl.handle.net/11452/48891Bu çalışma, 07-10 Aralık, 2019 tarihlerinde Orlando[Amerika]’da düzenlenen 61. Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/openAccessScience & technologyLife sciences & biomedicineHematologyMeeting Abstract000577164606194https://www.nature.com/articles/s41409-022-01613-w13410.1182/blood-2019-1264021528-0020